recent publications
-
academic article
- Austad, B. C., Calkins, T. L., Chase, C. E., Fang, F. G., Horstmann, T. E., Hu, Y., Lewis, B. M., Niu, X., Noland, T. A., Orr, J. D., Schnaderbeck, M. J., Zhang, H., et al. Commercial manufacture of Halaven: chemoselective transformations en route to structurally complex macrocyclic ketones Synlett 2013 24:333-337 DOI:10.1055/s-0032-1318026
- Chase, C. E., Fang, F. G., Lewis, B. M., Wilkie, G. D., Schnaderbeck, M. J., Zhu, X. Process development of Halaven: synthesis of the C1-C13 fragment from D-(-)-gulono-1,4-lactone Synlett 2013 24:323-326 DOI:10.1055/s-0032-1317919
- Austad, B. C., Benayoud, F., Calkins, T. L., Campagna, S., Chase, C. E., Choi, H. W., Christ, W., Costanzo, R., Cutter, J., Endo, A., Fang, F. G., Hu, Y., et al. Process development of Halaven: synthesis of the C14-C35 fragment via iterative Nozaki-Hiyama-Kishi reaction-Williamson ether cyclization Synlett 2013 24:327-332 DOI:10.1055/s-0032-1317920
- Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., Zheng, W., Seletsky, B. M., Zhu, X., Lewis, B. M., Kishi, Y., Yu, M. J., Littlefield, B. A. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions Cancer Research 2011 71:496-505 DOI:10.1158/0008-5472.can-10-1874 PMID:21127197
- Narayan, S., Carlson, E. M., Cheng, H., Du, H., Hu, Y., Jiang, Y., Lewis, B. M., Seletsky, B. M., Tendyke, K., Zhang, H., Zheng, W., Littlefield, B. A., et al. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility Bioorganic & Medicinal Chemistry Letters 2011 21:1630-1633 DOI:10.1016/j.bmcl.2011.01.111 PMID:21324686
- Narayan, S., Carlson, E. M., Cheng, H., Condon, K., Du, H., Eckley, S., Hu, Y., Jiang, Y., Kumar, V., Lewis, B. M., Saxton, P., Schuck, E., et al. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo Bioorganic & Medicinal Chemistry Letters 2011 21:1634-1638 DOI:10.1016/j.bmcl.2011.01.097 PMID:21324692
- Narayan, S., Carlson, E. M., Cheng, H., Condon, K., Du, H., Eckley, S., Hu, Y., Jiang, Y., Kumar, V., Lewis, B. M., Saxton, P., Schuck, E., et al. Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model Bioorganic & Medicinal Chemistry Letters 2011 21:1639-1643 DOI:10.1016/j.bmcl.2011.01.096 PMID:21324687
- Smith, J. A., Wilson, L., Azarenko, O., Zhu, X., Lewis, B. M., Littlefield, B. A., Jordan, M. A. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 2010 49:1331-1337 DOI:10.1021/bi901810u PMID:20030375 PMCID:PMC2846717
-
Boger, D. L., Hikota, M., Lewis, B. M.
Determination of the relative and absolute stereochemistry of fostriecin (CL-920)
Journal of Organic Chemistry
1997
62:1748-1753
DOI:10.1021/jo962166h
- Chen, B. C., Murphy, C. K., Kumar, A., Reddy, R. T., Clark, C., Zhou, P., Lewis, B. M., Gala, D., Mergelsberg, I., Scherer, D., Buckley, J., DiBenedetto, D., et al. (+)-(2R,8aR*)- (8,8-dimethoxycamphoryl)sulfonyl oxaziridine and (+)-(2R,8aR*)- (8,8-dichlorocamphoryl)sulfonyl oxaziridine - ( 4H-4a,7-methanooxazirino 3,2-i 2,1 benzisothiazole, tetrahydro-8,8-dimethoxy-9,9-dimethyl-, 3,3-dioxide , 2R-(2 alpha,4a alpha,7 alpha,8aR*) - and 4H-4a,7-methanooxazirino 3,2-i 2,1 benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethyl-, 3,3-dioxide, 2R-(2 alpha,4a alpha,7 alpha,8aR*) ) Organic Syntheses 1996 73:159-173 DOI:10.15227/orgsyn.073.0159
- Gilligan, P. J., Kergaye, A. A., Lewis, B. M., McElroy, J. F. Piperidinyltetralin sigma ligands Journal of Medicinal Chemistry 1994 37:364-370 DOI:10.1021/jm00029a008 PMID:7905926